Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18355892 | 0.90 | RXFP1 (0.44) | RXFP1NR1H4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18355930 | 0.88 | RXFP1 (0.43) | RXFP1NR1H4BRAFLMNAKMT2A | |
| SCHEMBL1766886 | 0.87 | RXFP1 (0.53) | RXFP1NR1H4BRAFKMT2AMLYCD | |
| SCHEMBL18355509 | 0.86 | RXFP1 (0.35) | RXFP1NR1H4ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18356119 | 0.86 | MLYCD (0.40) | RXFP1LMNASMN1; SMN2MLYCD | |
| SCHEMBL18355929 | 0.85 | RXFP1 (0.44) | RXFP1NR1H4BRAFSMN1; SMN2KMT2A | |
| SCHEMBL1767265 | 0.85 | RXFP1 (0.51) | RXFP1NR1H4BRAFKMT2AMLYCD | |
| SCHEMBL18355890 | 0.84 | RXFP1 (0.45) | RXFP1BRAFALDH1A1KMT2AMEN1 | |
| SCHEMBL1766681 | 0.83 | RXFP1 (0.52) | RXFP1NR1H4SMN1; SMN2MLYCD | |
| SCHEMBL18356116 | 0.83 | ALDH1A1 (0.36) | RXFP1BRAFALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9750246-B2 | Insecticidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2017-09-05 | — | — | US | disclosed |
| US-9750246-B2 | Insecticidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2017-09-05 | — | — | US | disclosed |
| US-20170000121-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2017-01-05 | — | — | US | disclosed |
| US-20170000121-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000121-A1 | INSECTICIDAL COMPOUNDS | ACHE, NIT2, CHRM1 | RXFP1 1005/4885NR1H4 2616/4885BRAF 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.